Tag: FOLD

Blue Horseshoe Stocks: AVOP, CETV, PBR Options

AV1 Group, Inc. AVOP

We’ve been tracking AVOP for a few weeks now, having already seen some pretty impressive moves from the stock. Our initial alerts lead to gains in excess of 200%, and we saw another spike yesterday which led to AVOP coming down to .0012 from a high of .0027.

The stock closed out the day at .0016, and it seems to be searching for a bottom, so we’ll be monitoring for that eventuality. As volatile as trading in AVOP is, a properly timed bottom play could yield significant gains.

In order to remain interested in AVOP, we’ll want to see it hold support at or above its recent base range of .001-.0012.

Central European Media Enterprises Ltd. CETV

It’s been quite some time since we caught CETV on a Form-4 scan back in 2013. We followed the stock to highs well over 6.00 back in October.

After searching out a bottom, CETV again surged from the 2.10-range to the 3.40’s from November, and leading up to the beginning of 2014.

The stock produced yet another spike at the end of February that carried it from under 3.00 to nearly 5.00.

We come across this play as it is once again in a bottom-searching pattern. With the kind of moves this thing has made for us in the past, popping after big consolidations, we would be remiss to ignore its potential once it does find solid support and a subsequent rebound.

Petroleo Brasiliero SA (Petrobras) PBR

The PBR options chain has been very kind to us in recent months. When we first introduced this play on March 21st, the stock was trading at a low of 11.25.

It seems every time we called out our interest in a particular set of contracts in the weeks that followed, the gains would pile on, often to the tune of 100% or more. A quick scan through our PBR archive will confirm just how many times we took advantage of this stock’s recovery.

After peaking at a high of 14.87 on April 8th, the stock came back to bounce off support at 12.98 on April 15th.

Since then, it has been testing the boundary at $14, and hit a high of 14.03 yesterday, and already in the pre-market the stock is trading as high as 14.10, so we’ll try to take advantage of the trend using options.

We’ll be monitoring the $13.50 and $14 Weekly Calls throughout the rest of the week for potential dip-and-rip opportunities.

Extended Watchlist:
S, NOK, BSBR, FOLD, NVAX, OXGN

Blue Horseshoe Kicks Off 2013 With a Bang

We ended 2012 on a high note, and as anticipated, started 2013 off with a bang. We have found several high flying runners this week. We have noticed a heightened liquidity in the penny markets, and its a great feeling to see the momentum providing us with opportunity to make triple digit gains left and right. The following is a list of just a few of our winners so far this year.
___

AXCG appeared on our extended watchlist on Jan.4th, AXCG was as low as .0006 at the time, and at yesterday’s high of .0026, we have had the opportunity for up to 333% in gains. Both AXCG and NOK earned us top spot in the Penny Stock Rumble after appearing in yesterday’s report .

___

Aqualiv Technologies, Inc. AQLV

AQLV was another prime example of high volume high volitility action after we included it in our extended watchlist Wednesday afternoon and Thursday morning.

The stock had some news earlier in the week, pointing to a new acquisition which adds approximately $4.5M in total assets to the balance sheet; another reason we’ll be following this play into the foreseeable future.

AQLV Video Chart

___

Sitoa Global Inc. STOA

Early in the week, we caught STOA from .0095-.065, racking in 584% in just two trading sessions.

___

Amicus Therapeutics, Inc. FOLD

We started tracking FOLD last Friday, taking notice of a huge gap on chart dating back to December that needed to be filled. So far FOLD has traded from 3.45-4.23 for a gain of 23%

The RSI and the Slow STO both got above the 50-line and the 50MA overlay, and the histogram recently flipped up to the bullish side, continuing to build up. The PPO just crossed over, and is diverging. All in all the chart on FOLD currently has a nice set-up.

___

Gulf United Energy, Inc. GLFE

We are presenting GLFE as a momentum play this morning after catching it on our scanners yesterday. We posted a blurb on our Facebook pages in the afternoon at .004, and saw a subsequent high of .0059, for a nearly 50% rip.

___

Scout Exploration, Inc. SCXN

SCXN has appeared on our watchlists a few times this year, and we are adding it as a focus today as the stock is moving above its moving averages, and setting up for what could be its next run.

SCXN’s previous high was at .39. A return to those levels from the current price would reflect gains of roughly 30%, a break past, and we are in blue-sky territory.

SCXN Video Chart

___

Extended Watchlist:

UPIP, DNDN, ERBB, AAPT, AMBS

SAFC, PPHM, BTHR & Extended Watchlist

We wanted to bring SAFC to your attention this morning, as a number of factors is causing us to keep a watchful eye. The company recently announced a share buyback program for the month of January wherein 1,000,000 shares will be bought at up to $0.20 per share. We are also seeing a stock coming off of a recent bottom; on Friday it rose 15% on light volume. This often indicates a tightly-held, low-float play, upon which any surge of buying can act as a catalyst for much larger increases.

It is for those reasons that we kick off our week keeping an eye on SAFC.

___

Peregrine Pharmaceuticals, Inc. PPHM

We’ve seen a lot from PPHM in the roughly 5 months we’ve been monitoring the stock. With our first mention coming on August 14th, and focusing more intently in the weeks that followed, we saw PPHM rise from the 1.80’s all the way up to 5.50 on Sept. 21st. It was at that time we observed a huge sell-off, in fact the stock has been as low as .68 as recently as November.

___

Big Three Restaurants, Inc. BTHR

BTHR was as low as .0012 when it appeared on our watchlist on Wednesday. On Friday the stock closed at the high-of-day of .0022, for a gain of 83% in just two day’s time.

___

Extended Watchlist:

ABAT, AMBS, BMSN, MWIP, VSUT, STOA, FOLD

FOLD, MWIP & Extended Watchlist

FOLD caught our attention yesterday as an intriguing pharmaceutical play that recently underwent some panic selling, and is now coming off of the resultant bottom.First a little back-story: Amicus has been teamed up with pharma giant, GlaxoSmithKline (GSK), running clinical trials on a drug called migalastat HCI, meant to treat a rare disease in which a genetic mutation prevents enzymes from breaking down a fatty substance referred to as GL-3. As a result, GL-3 build up in the kidneys can lead to organ failure and death.

The big sell-off occurred back in late December when the duo announced that the study, statistically, failed to meet their objectives after a 6 month period, making a fast-track to FDA approval an impossibility.

The encouraging news, and the reason we think now is a prime time to take a look at FOLD, is that the studies do not conclude at the 6 month point; they have continued, and the 12 month results are expected to come early in 2013. While failing to meet project goals, there was still a 50% reduction in GL-3 buildup in 41% of the migalastat HCI group, as compared to just 28% of the placebo group. The 12-month results will be accompanied by the company meeting FDA officials to discuss the track to approval, and how it is altered by the results of trials still underway.

John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 9, 2013 at 3:00 p.m. PT. which can be viewed via a LIVE WEBCAST on the specified date and time.

What really jumps out to us, is simply the fact that FOLD recently saw a big gap down, and has now begun to recover. Often in the past we’ve seen cases such as this where the stock bounces back to fill the gap, offering up great opportunities for gain.

It could also come to that sooner, rather than later- The company also has other irons in the fire, as this morning it released a PR regarding another of its drugs currently in testing phases, this time with positive results:


Amicus Therapeutics Announces Positive Results From All Four Cohorts in Phase 2 Chaperone-Enzyme Replacement Therapy (ERT) Co-Administration Study for Pompe Disease

CRANBURY, N.J., Jan 04, 2013 (GLOBE NEWSWIRE via COMTEX) — Strong Proof-of-Concept Data for Chaperone’s Ability to Stabilize and Enhance Activity and Uptake of Currently Marketed ERT Products for Pompe Disease

Results to be Presented at LDN WORLD Symposium in February 2013

Initiation of Repeat-Dose Pompe Study Anticipated in 3Q13

Amicus Therapeutics (Nasdaq: FOLD) today announced positive preliminary results from all 4 dose cohorts in a Phase 2 study (Study 010) to evaluate the safety and pharmacokinetic (PK) effects of the pharmacological chaperone AT2220 (duvoglustat HCl) co-administered with enzyme replacement therapy (ERT) for Pompe disease (Myozyme and Lumizyme). Myozyme and Lumizyme (alglucosidase alfa, or recombinant human GAA enzyme, rhGAA) are the first and only approved treatments for Pompe disease.

___

We will be continuing to follow this play, and keep everyone updated as more details arise.

___

MediSwipe, Inc. MWIP

A lot of you may have missed our last report before the holidays, in which we mentioned that we would like to see MWIP continue to hold support above a penny and test its previous highs. Yesterday saw the stock break past its previous high of .0199 into blue-sky territory, hitting a high of .0289, earning us a spot on the Penny Stock Rumble with a gain of 50%

In total, from the low following our first mention of MWIP back at .0024, yesterday’s high marks an astonishing 1104% gain.

If and when we see a pullback on MWIP, we want to see the previous resistance of .0199 hold as a future level of support for us to remain bullish.

___

Extended Watchlist:

UNLA, AHFD, AXCG, SAPX, SFAZ, ZLCS

Get Our FREE Daily Reports!

SUBSCRIBE